Clinically relevant correction of recessive dystrophic epidermolysis bullosa by dual sgRNA CRISPR/Cas9-mediated gene editing
Gene editing constitutes a novel approach for precisely correcting disease-causing gene mutations. Frameshift mutations in COL7A1 causing recessive dystrophic epidermolysis bullosa are amenable to open reading frame restoration by non-homologous end joining repair-based approaches. Efficient targete...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
15 March 2019
|
| In: |
Molecular therapy
Year: 2019, Jahrgang: 27, Heft: 5, Pages: 986-998 |
| ISSN: | 1525-0024 |
| DOI: | 10.1016/j.ymthe.2019.03.007 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.ymthe.2019.03.007 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1525001619300930 
|
| Verfasserangaben: | Jose Bonafont, Ángeles Mencía, Marta García, Raúl Torres, Sandra Rodríguez, Marta Carretero, Esteban Chacón-Solano, Silvia Modamio-Høybjør, Lucía Marinas, Carlos León, María J. Escamez, Ingrid Hausser, Marcela Del Río, Rodolfo Murillas, and Fernando Larcher |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1690133171 | ||
| 003 | DE-627 | ||
| 005 | 20240404193233.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200217s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ymthe.2019.03.007 |2 doi | |
| 035 | |a (DE-627)1690133171 | ||
| 035 | |a (DE-599)KXP1690133171 | ||
| 035 | |a (OCoLC)1341305528 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Bonafont, Jose |e VerfasserIn |0 (DE-588)1204942722 |0 (DE-627)1690243368 |4 aut | |
| 245 | 1 | 0 | |a Clinically relevant correction of recessive dystrophic epidermolysis bullosa by dual sgRNA CRISPR/Cas9-mediated gene editing |c Jose Bonafont, Ángeles Mencía, Marta García, Raúl Torres, Sandra Rodríguez, Marta Carretero, Esteban Chacón-Solano, Silvia Modamio-Høybjør, Lucía Marinas, Carlos León, María J. Escamez, Ingrid Hausser, Marcela Del Río, Rodolfo Murillas, and Fernando Larcher |
| 246 | 3 | 0 | |a nine |
| 264 | 1 | |c 15 March 2019 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 17.02.2020 | ||
| 520 | |a Gene editing constitutes a novel approach for precisely correcting disease-causing gene mutations. Frameshift mutations in COL7A1 causing recessive dystrophic epidermolysis bullosa are amenable to open reading frame restoration by non-homologous end joining repair-based approaches. Efficient targeted deletion of faulty COL7A1 exons in polyclonal patient keratinocytes would enable the translation of this therapeutic strategy to the clinic. In this study, using a dual single-guide RNA (sgRNA)-guided Cas9 nuclease delivered as a ribonucleoprotein complex through electroporation, we have achieved very efficient targeted deletion of COL7A1 exon 80 in recessive dystrophic epidermolysis bullosa (RDEB) patient keratinocytes carrying a highly prevalent frameshift mutation. This ex vivo non-viral approach rendered a large proportion of corrected cells producing a functional collagen VII variant. The effective targeting of the epidermal stem cell population enabled long-term regeneration of a properly adhesive skin upon grafting onto immunodeficient mice. A safety assessment by next-generation sequencing (NGS) analysis of potential off-target sites did not reveal any unintended nuclease activity. Our strategy could potentially be extended to a large number of COL7A1 mutation-bearing exons within the long collagenous domain of this gene, opening the way to precision medicine for RDEB. | ||
| 650 | 4 | |a CRISPR/Cas9 | |
| 650 | 4 | |a epidermal stem cells | |
| 650 | 4 | |a epidermolysis bullosa | |
| 650 | 4 | |a gene therapy | |
| 700 | 1 | |a Haußer-Siller, Ingrid |d 1957- |e VerfasserIn |0 (DE-588)1058096710 |0 (DE-627)796384703 |0 (DE-576)163782377 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular therapy |d Amsterdam : Elsevier, 2000 |g 27(2019), 5, Seite 986-998 |h Online-Ressource |w (DE-627)320415198 |w (DE-600)2001818-6 |w (DE-576)104344695 |x 1525-0024 |7 nnas |a Clinically relevant correction of recessive dystrophic epidermolysis bullosa by dual sgRNA CRISPR/Cas9-mediated gene editing |
| 773 | 1 | 8 | |g volume:27 |g year:2019 |g number:5 |g pages:986-998 |g extent:13 |a Clinically relevant correction of recessive dystrophic epidermolysis bullosa by dual sgRNA CRISPR/Cas9-mediated gene editing |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ymthe.2019.03.007 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1525001619300930 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200217 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1058096710 |a Haußer-Siller, Ingrid |m 1058096710:Haußer-Siller, Ingrid |d 910000 |d 912000 |e 910000PH1058096710 |e 912000PH1058096710 |k 0/910000/ |k 1/910000/912000/ |p 12 | ||
| 999 | |a KXP-PPN1690133171 |e 3595971701 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"15 March 2019"}],"title":[{"title":"Clinically relevant correction of recessive dystrophic epidermolysis bullosa by dual sgRNA CRISPR/Cas9-mediated gene editing","title_sort":"Clinically relevant correction of recessive dystrophic epidermolysis bullosa by dual sgRNA CRISPR/Cas9-mediated gene editing"}],"person":[{"display":"Bonafont, Jose","family":"Bonafont","role":"aut","roleDisplay":"VerfasserIn","given":"Jose"},{"given":"Ingrid","roleDisplay":"VerfasserIn","role":"aut","family":"Haußer-Siller","display":"Haußer-Siller, Ingrid"}],"physDesc":[{"extent":"13 S."}],"note":["Gesehen am 17.02.2020"],"id":{"doi":["10.1016/j.ymthe.2019.03.007"],"eki":["1690133171"]},"relHost":[{"note":["Gesehen am 28.05.2020"],"id":{"eki":["320415198"],"zdb":["2001818-6"],"issn":["1525-0024"]},"recId":"320415198","disp":"Clinically relevant correction of recessive dystrophic epidermolysis bullosa by dual sgRNA CRISPR/Cas9-mediated gene editingMolecular therapy","type":{"media":"Online-Ressource","bibl":"periodical"},"physDesc":[{"extent":"Online-Ressource"}],"part":{"pages":"986-998","text":"27(2019), 5, Seite 986-998","issue":"5","extent":"13","volume":"27","year":"2019"},"language":["eng"],"origin":[{"publisherPlace":"Amsterdam ; New York, NY ; Orlando, Fla.","dateIssuedKey":"2000","dateIssuedDisp":"2000-","publisher":"Elsevier ; Nature Publ. Group ; Acad. Press"}],"corporate":[{"roleDisplay":"Herausgebendes Organ","role":"isb","display":"American Society of Gene Therapy"}],"pubHistory":["1.2000 -"],"title":[{"subtitle":"official journal of the American Society of Gene Therapy","title":"Molecular therapy","title_sort":"Molecular therapy"}]}],"name":{"displayForm":["Jose Bonafont, Ángeles Mencía, Marta García, Raúl Torres, Sandra Rodríguez, Marta Carretero, Esteban Chacón-Solano, Silvia Modamio-Høybjør, Lucía Marinas, Carlos León, María J. Escamez, Ingrid Hausser, Marcela Del Río, Rodolfo Murillas, and Fernando Larcher"]},"language":["eng"],"recId":"1690133171"} | ||
| SRT | |a BONAFONTJOCLINICALLY1520 | ||